Skip to main content

Drug Pricing Reform Unlikely to Affect Smaller Biotech Companies

Investing in healthcare stocks is compelling for many investors because of the defensive qualities of blue chip pharmaceuticals companies and the growth prospects of biotechnology names. However, as sustainable investing becomes an increasingly prominent part of the investment lexicon, some may...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.